Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1
| Autor: | M.H. Nielsen, E.S. Yates, Ingelise Jensen, M.S. Thomsen, Giulio Francolini, Andreas Schreiber, Claus Kamby, Ingvil Mjaaland, Mechthild Krause, Unn miriam Kasti, Carine Kirkove, Birgitte Vrou Offersen, Martin Berg, Kristian Boye, Egil S. Blix |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Organs at Risk
medicine.medical_treatment Planning target volume Automated segmentation Breast Neoplasms Dose planning 03 medical and health sciences 0302 clinical medicine Breast cancer Skagen Trial 1 medicine Journal Article Humans Radiology Nuclear Medicine and imaging 030212 general & internal medicine Early breast cancer Observer Variation Contouring business.industry Quality assessment Radiotherapy Planning Computer-Assisted Radiotherapy Dosage Hematology Delineation medicine.disease Radiation therapy Oncology 030220 oncology & carcinogenesis Female Nuclear medicine business |
| Zdroj: | Francolini, G, Thomsen, M S, Yates, E S, Kirkove, C, Jensen, I, Blix, E S, Kamby, C, Nielsen, M H, Krause, M, Berg, M, Mjaaland, I, Schreiber, A, Kasti, U-M, Boye, K & Offersen, B V 2017, ' Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1 ', Radiotherapy & Oncology, vol. 123, no. 2, pp. 282-287 . https://doi.org/10.1016/j.radonc.2017.03.011 Francolini, G, Thomsen, M S, Yates, E S, Kirkove, C, Jensen, I, Blix, E S, Kamby, C, Holck Nielsen, M, Krause, M, Berg, M, Mjaaland, I, Schreiber, A, Kasti, U M, Boye, K & Offersen, B V 2017, ' Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1 ', Radiotherapy & Oncology, vol. 123, no. 2, pp. 282–287 . https://doi.org/10.1016/j.radonc.2017.03.011 Radiotherapy and Oncology 123(2017)2, 282-287 |
| Popis: | BACKGROUND AND PURPOSE:To report on a Quality assessment (QA) of Skagen Trial 1, exploring hypofractionation for breast cancer patients with indication for regional nodal radiotherapy.MATERIAL AND METHODS:Deviations from protocol regarding target volume delineations and dose parameters (Dmin, Dmax, D98%, D95% and D2%) from randomly selected dose plans were assessed. Target volume delineation according to ESTRO guidelines was obtained through atlas based automated segmentation and centrally approved as gold standard (GS). Dice similarity scores (DSC) with original delineations were measured. Dose parameters measured in the two delineations were reported to assess their dosimetric outcome.RESULTS:Assessment included 88 plans from 12 centres in 4 countries. DSC showed high agreement in contouring, 99% and 96% of the patients had a complete delineation of target volumes and organs at risk. No deviations in the dosimetric outcome were found in 76% of the patients, 82% and 95% of the patients had successful coverage of breast/chestwall and CTVn_L2-4-interpectoral. Dosimetric outcomes of original delineation and GS were comparable.CONCLUSIONS:QA showed high protocol compliance and adequate dose coverage in most patients. Inter-observer variability in contouring was low. Dose parameters were in harmony with protocol regardless original or GS segmentation. BACKGROUND AND PURPOSE: To report on a Quality assessment (QA) of Skagen Trial 1, exploring hypofractionation for breast cancer patients with indication for regional nodal radiotherapy.MATERIAL AND METHODS: Deviations from protocol regarding target volume delineations and dose parameters (Dmin, Dmax, D98%, D95% and D2%) from randomly selected dose plans were assessed. Target volume delineation according to ESTRO guidelines was obtained through atlas based automated segmentation and centrally approved as gold standard (GS). Dice similarity scores (DSC) with original delineations were measured. Dose parameters measured in the two delineations were reported to assess their dosimetric outcome.RESULTS: Assessment included 88 plans from 12 centres in 4 countries. DSC showed high agreement in contouring, 99% and 96% of the patients had a complete delineation of target volumes and organs at risk. No deviations in the dosimetric outcome were found in 76% of the patients, 82% and 95% of the patients had successful coverage of breast/chestwall and CTVn_L2-4-interpectoral. Dosimetric outcomes of original delineation and GS were comparable.CONCLUSIONS: QA showed high protocol compliance and adequate dose coverage in most patients. Inter-observer variability in contouring was low. Dose parameters were in harmony with protocol regardless original or GS segmentation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|